Research Article

Validation of Kinetic Stem Cell (KSC) counting algorithms for rapid quantification of human hematopoietic stem cells

James L Sherley*, Michael P Daley and Renly A Dutton

Published: 28 November, 2022 | Volume 6 - Issue 1 | Pages: 029-037

Specific quantification of therapeutic tissue stem cells (TSCs) is a major challenge. We recently described a computational simulation method for accurate and specific counting of TSCs. The method quantifies TSCs based on their unique asymmetric cell kinetics, which is rate-limiting for TSCs’ production of transiently-amplifying lineage-committed cells and terminally arrested cells during serial cell culture. Because of this basis, the new method is called kinetic stem cell (KSC) counting. Here, we report further validations of the specificity and clinical utility of KSC counting. First, we demonstrate its quantification of the expected increase in the hematopoietic stem cell (HSC) fraction of CD34+-selected preparations of human-mobilized peripheral blood cells, an approved treatment product routinely used for HSC transplantation therapies. Previously, we also used the KSC counting technology to define new mathematical algorithms with the potential for rapid determination of TSC-specific fractions without the need for serial culture. A second important HSC transplantation treatment, CD34+-selected umbilical cord blood (UCB) cells, was used to investigate this prediction. We show that, with an input of only simple population doubling time (PDT) data, the KSC counting-derived “Rabbit algorithms” can be used to rapidly determine the specific HSC fraction of CD34+-selected UCB cell preparations with a high degree of statistical confidence. The algorithms define the stem cell fraction half-life (SCFHL), a new parameter that projects stem cell numbers during expansion culture. These findings further validate KSC counting’s potential to meet the long-standing unmet need for a method to determine stem cell-specific dosage in stem cell medicine.

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001028 Cite this Article Read Full Article PDF


Hematopoietic stem cell; Apheresis; Mobilization; CD34; Cord blood; Stem cell transplantation; Algorithm


  1. Ivanovic Z. Hematopoietic stem cells in research and clinical applications: The "CD34 issue". World J Stem Cells. 2010 Apr 26;2(2):18-23. doi: 10.4252/wjsc.v2.i2.18. PMID: 21607112; PMCID: PMC3097920.
  2. Sherley JL. Principles for targeting adult tissue stem cells to achieve durable gene and gene-editing therapeutics. In: Appasani K, ed. Genome Editing and Engineering: From Talens, ZFN, and CRISPRs to Molecular Surgery. Cambridge: Cambridge University Press, 2018:285-300.
  3. Sherley JL. Dose determination for stem cell medicine: a need whose time has come. In: Atala A, Cetrulo C, Cetrulo K, Murphy SV, Taghizadeh R, eds. Perinatal Stem Cells: Research and Therapy. Amsterdam: Elsevier, 2018:383-397.
  4. Sherley JL. Stem cell therapy: resolving the mismatch. Pharmaceutical Manufacturing. 2018; 38-41.
  5. Sherley JL. Achieving dose standardization for the stem cell clinical trials industry. Operations 10:03, May 31, 2018; http://www.clinicaltrialsarena.com/news/operations/achieving-dose-standardization-for-the-stem-cell-clinical-trials-industry-6172126.
  6. Sherley JL. Why don’t stem-gene clinical trial sponsors count their stem cells? Arena Intl. Events Grp. H1 Virtual Events: Review and Summary Handbook 2021; 14-16. https://content.yudu.com/web/442ay/0A447nd/H1VE-RSH21/html/index.html?page=2&origin=reader.
  7. Kassar-Duchossoy L, Giacone E, Gayraud-Morel B, Jory A, Gomès D, Tajbakhsh S. Pax3/Pax7 mark a novel population of primitive myogenic cells during development. Genes Dev. 2005 Jun 15;19(12):1426-31. doi: 10.1101/gad.345505. PMID: 15964993; PMCID: PMC1151658.
  8. Yin H, Price F, Rudnicki MA. Satellite cells and the muscle stem cell niche. Physiol Rev. 2013 Jan;93(1):23-67. doi: 10.1152/physrev.00043.2011. PMID: 23303905; PMCID: PMC4073943.
  9. Huh YH, Noh M, Burden FR, Chen JC, Winkler DA, Sherley JL. Sparse feature selection identifies H2A.Z as a novel, pattern-specific biomarker for asymmetrically self-renewing distributed stem cells. Stem Cell Res. 2015 Mar;14(2):144-54. doi: 10.1016/j.scr.2014.12.007. Epub 2015 Jan 6. PMID: 25636161; PMCID: PMC4363179.
  10. Homma S, Chen JC, Rahimov F, Beermann ML, Hanger K, Bibat GM, Wagner KR, Kunkel LM, Emerson CP Jr, Miller JB. A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. Eur J Hum Genet. 2012 Apr;20(4):404-10. doi: 10.1038/ejhg.2011.213. Epub 2011 Nov 23. PMID: 22108603; PMCID: PMC3306860.
  11. L Ramos T, Sánchez-Abarca LI, Muntión S, Preciado S, Puig N, López-Ruano G, Hernández-Hernández Á, Redondo A, Ortega R, Rodríguez C, Sánchez-Guijo F, del Cañizo C. MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry. Cell Commun Signal. 2016 Jan 12;14:2. doi: 10.1186/s12964-015-0124-8. PMID: 26754424; PMCID: PMC4709865.
  12. Purton LE, Scadden DT. Limiting factors in murine hematopoietic stem cell assays. Cell Stem Cell. 2007 Sep 13;1(3):263-70. doi: 10.1016/j.stem.2007.08.016. PMID: 18371361.
  13. Dutton R, Abdi F, Minnetyan L, Sherley JL. A computational technology for specific counting of perinatal and postnatal human tissue stem cells for transplantation medicine,” OBM Transplantation. 2020; 4:24; doi:10.21926/obm.transplant.2003117.
  14. Paré JF, Sherley JL. Biological principles for ex vivo adult stem cell expansion. In: Schatten G, ed. Current Topics in Developmental Biology. 73. San Diego: Elsevier Inc., 2006; 73: 141-171.
  15. Rambhatla L, Bohn SA, Stadler PB, Boyd JT, Coss RA, Sherley JL. Cellular Senescence: Ex Vivo p53-Dependent Asymmetric Cell Kinetics. J Biomed Biotechnol. 2001;1(1):28-37. doi: 10.1155/S1110724301000079. PMID: 12488624; PMCID: PMC79675.
  16. Merok JR, Sherley JL. Breaching the Kinetic Barrier to In Vitro Somatic Stem Cell Propagation. J Biomed Biotechnol. 2001;1(1):25-27. doi: 10.1155/S1110724301000067. PMID: 12488623; PMCID: PMC79674.
  17. Sherley JL. New cancer diagnostics and therapeutics from a ninth 'hallmark of cancer': symmetric self-renewal by mutated distributed stem cells. Expert Rev Mol Diagn. 2013 Nov;13(8):797-810. doi: 10.1586/14737159.2013.845087. PMID: 24151848.
  18. Potten CS, Morris RJ. Epithelial stem cells in vivo. J Cell Sci Suppl. 1988;10:45-62. doi: 10.1242/jcs.1988.supplement_10.4. PMID: 3077942.
  19. Loeffler M, Potten CS. Stem cells and cellular pedigrees - a conceptual In: Potten CS, ed. Stem Cells. San Diego: Harcourt Brace & Co. 1997: 1-28.
  20. McDermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood. 2010 Jul 15;116(2):193-200. doi: 10.1182/blood-2010-02-271841. Epub 2010 Apr 19. PMID: 20404133.
  21. Nowlan B, Williams ED, Doran MR, Levesque JP. CD27, CD201, FLT3, CD48, and CD150 cell surface staining identifies long-term mouse hematopoietic stem cells in immunodeficient non-obese diabetic severe combined immune deficient-derived strains. Haematologica. 2020 Jan;105(1):71-82. doi: 10.3324/haematol.2018.212910. Epub 2019 May 9. PMID: 31073070; PMCID: PMC6939540.
  22. Hayflick l. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965 Mar;37:614-36. doi: 10.1016/0014-4827(65)90211-9. PMID: 14315085.
  23. Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, Ringden O. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013 Apr;48(4):537-43. doi: 10.1038/bmt.2012.239. Epub 2012 Dec 10. Erratum in: Bone Marrow Transplant. 2013 Apr;48(4):616. PMID: 23222384.


Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?